Akebia Therapeutics (AKBA) Scheduled to Post Earnings on Thursday

Akebia Therapeutics (NASDAQ:AKBA) is scheduled to be issuing its quarterly earnings data before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of ($0.09) per share for the quarter. Investors that wish to listen to the company’s conference call can do so using this link.

Akebia Therapeutics (NASDAQ:AKBA) last issued its quarterly earnings results on Thursday, March 14th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.04). The company had revenue of $56.20 million during the quarter, compared to analysts’ expectations of $55.64 million. During the same period in the prior year, the business posted ($0.04) EPS. On average, analysts expect Akebia Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Akebia Therapeutics Price Performance

Akebia Therapeutics stock opened at $1.40 on Wednesday. Akebia Therapeutics has a fifty-two week low of $0.78 and a fifty-two week high of $2.48. The firm’s 50 day simple moving average is $1.56 and its 200-day simple moving average is $1.36. The company has a market cap of $293.12 million, a P/E ratio of -5.00 and a beta of 0.94.

Insider Buying and Selling at Akebia Therapeutics

In other news, CEO John P. Butler sold 46,570 shares of the stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $1.58, for a total transaction of $73,580.60. Following the sale, the chief executive officer now directly owns 2,044,580 shares of the company’s stock, valued at $3,230,436.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other Akebia Therapeutics news, CEO John P. Butler sold 37,733 shares of the firm’s stock in a transaction that occurred on Tuesday, February 27th. The shares were sold at an average price of $1.52, for a total value of $57,354.16. Following the transaction, the chief executive officer now directly owns 2,091,150 shares of the company’s stock, valued at $3,178,548. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO John P. Butler sold 46,570 shares of the stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $1.58, for a total value of $73,580.60. Following the completion of the transaction, the chief executive officer now directly owns 2,044,580 shares in the company, valued at approximately $3,230,436.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 117,093 shares of company stock worth $181,654. 3.84% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. StockNews.com lowered shares of Akebia Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, April 29th. HC Wainwright raised their price target on shares of Akebia Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Thursday, March 28th.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.